|Day's range||0.00 - 0.00|
|PE ratio (TTM)||77.14|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
A U.S. unit of British drug company BTG Plc pleaded guilty on Monday to a misdemeanor related to its misbranding of the embolic device LC Bead, and will pay about $36 million to resolve its criminal and ...
British healthcare group BTG Plc said it agreed to settle an investigation into one of its U.S. units, Biocompatibles, with the U.S. Department of Justice for $36 million. BTG said its 2016-17 forecast for selling, general and administrative expenses did not include the effect of the settlement. BTG agreed to settle all allegations regarding the investigation, which focused on the period before it acquired the oncology products supplier Biocompatibles in 2011.
** Drugmaker Shire's model for growth, whereby successful products ramped up its valuation, giving it clout to make ever more expensive acquisitions, is taking seed in smaller rival BTG ** BTG's pioneering ...